<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5992">
  <stage>Registered</stage>
  <submitdate>11/03/2016</submitdate>
  <approvaldate>11/03/2016</approvaldate>
  <nctid>NCT02718716</nctid>
  <trial_identification>
    <studytitle>Study to Evaluate Safety, Tolerability and Efficacy of UCB7665 in Subjects With Primary Immune Thrombocytopenia</studytitle>
    <scientifictitle>A Multicenter, Open-label, Multiple-dose Study to Evaluate the Safety, Tolerability, and Efficacy of UCB7665 in Subjects With Primary Immune Thrombocytopenia</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>TP0001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Thrombocytopenia</healthcondition>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Haematological diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Other blood disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Autoimmune diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - UCB7665

Experimental: UCB7665 dose 1 - Subjects in this Arm will receive 5 subcutaneous (sc) doses of UCB7665 at 1-week intervals

Experimental: UCB7665 dose 2 - Subjects in this Arm will receive 3 subcutaneous (sc) doses of UCB7665 at 1-week intervals


Treatment: drugs: UCB7665
Intervention Type: Biological/Vaccine
Pharmaceutical Form: Powder for solution for infusion
Concentration: 100 mg/ml - Route of Administration:
Subcutaneous infusion

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Subjects experiencing at least one Treatment Emergent Event (TEAE) during the study - TEAEs are defined as Adverse Events starting after the time of first Investigational Medicinal Product (IMP) administration up to and including 8 weeks after the final dose.</outcome>
      <timepoint>From Visit 2 (Week 1) until End of Study Visit or Early Termination (up to 12 weeks after the first IMP administration)</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Subject has a diagnosis of primary immune thrombocytopenia (ITP) for a minimum of 3
             months prior to Screening Visit

          -  Subject has a platelet count &lt;30x10^9/L at Screening and &lt;35x10^9/L at Baseline (Visit
             2)

          -  Subject has a current or history of a peripheral blood smear consistent with ITP

          -  Subject has responded to previous ITP therapy (according to the judgment of the
             investigator)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Subject has an immunoglobulin G (IgG) level =6g/L at Screening Visit

          -  Subject has a partial thromboplastin time (PTT) =1.5x upper limit of normal (ULN) or
             International Normalized Ratio (INR) =1.5 at Screening Visit

          -  Subject has renal and/or liver impairment defined as:

        Serum creatinine level of =1.4 mg/dL for females and =1.5 mg/dL for males at Screening
        Visit

          -  Subject has planned an elective surgical procedure in the coming 6 months

          -  Subject has evidence of a secondary cause of primary immune thrombocytopenia purpura

          -  Subject has a history of clinically relevant ongoing chronic infections

          -  Subject has a family history of primary immunodeficiency

          -  Subject has a clinically relevant active infection or has had a serious infection
             within 6 weeks prior to the first dose of IMP

          -  Subject has a history of known inflammatory bowel disease, diverticular disease, and
             gastric or esophageal ulceration

          -  Subject has experienced gastrointestinal bleed in the last 6 months prior to Screening
             Visit and/or has current gastritis or esophagitis

          -  Subject has a medical history of thrombosis

          -  Subject has a history of coagulopathy disorders other than ITP

          -  Subject has received a live vaccination within 8 weeks prior to the Baseline Visit; or
             intends to have a live vaccination during the course of the study or within 7 weeks
             following the final dose of IMP

          -  Subject has had prior treatment with rituximab in the 6 months prior to the Baseline
             Visit

          -  Subject has not completed the washout period for the immunosuppressants, biologics and
             other therapies</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/06/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
    <hospital>Tp0001 1101 - Adelaide</hospital>
    <hospital>Tp0001 1102 - Box Hill</hospital>
    <postcode> - Adelaide</postcode>
    <postcode> - Box Hill</postcode>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brugge</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Pleven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Sofia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Olomouc</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Praha 10</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Georgia</country>
      <state>Tbilisi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Dusseldorf</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Essen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Gie√üen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Muenchen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Firenze</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Roma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Torino</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Udine</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Vicenza</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Lithuania</country>
      <state>Kaunas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Moldova, Republic of</country>
      <state>Chisinau</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Bialystok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Gdanks</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lodz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Poznan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Brasov</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Bucharest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Romania</country>
      <state>Craiova</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Valencia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>London</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Truro</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>UCB Biopharma S.P.R.L.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Parexel</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary objective of the study is to check if an subcutaneous (sc) infusion of UCB7665 is
      safe and tolerated in subjects with primary immune thrombocytopenia.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02718716</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>UCB Cares</name>
      <address>+1-844-599-2273 (UCB)</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>UCB Cares</name>
      <address />
      <phone>+1844599</phone>
      <fax />
      <email>UCBCares@ucb.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>